PRESS-RELEASE ·Filed Jun 30, 2026
Press release: earnings
Actionable Insight • Neutral
This is a routine earnings date announcement with zero financial content. No trading action warranted. Monitor the August 4 report for paltusotine commercial ramp and atumelnant pipeline updates.
Latest settled — T+20d
CRNX ▲ +116.86% at T+20d
NEUTRAL call ✓ call won +116.86% · α vs SPY +119.04% · entry $38.68 → $83.88
Latest observation: T+45 +89.42% FF3 residual α
T+1d
+9.18%
call +9.18% · α +9.31%
$42.23
settled 3mo ago
T+5d
+115.95%
call +115.95% · α +115.69%
$83.53
settled 3mo ago
T+20d
+116.86%
call +116.86% · α +119.04%
$83.88
settled 2mo ago
T+60d
—
call — · α —
—
due 8d ago
Price Chart
Loading chart...
Executive Summary
Crinetics Pharmaceuticals announced Q2 2026 earnings will be reported on August 4. The release contains no Q1 financial results — only a date announcement.
Key Facts
- Earnings call scheduled for August 4, 2026 at 4:30pm ET
- No Q1 2026 financial results disclosed in this press release
- Market cap is $3.9B; 91% of analysts rate as Buy/Strong Buy
Financial Impact
No financial data in this filing
Risk Factors
- Commercial execution risk for PALSONIFY (paltusotine) in acromegaly
- Clinical trial risk for atumelnant in congenital adrenal hyperplasia and Cushing's
- Historical reports on CRNX show 17% win rate at T+20; prior bullish reads underperformed materially
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3320099 |
15 reports for CRNX
78% Hit rate best @ T+20▲ +138.24%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 15-12G | — | awaiting T+1 | — | — |
Sep 1, 2026 4w ago | 25-NSE | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Sep 1, 2026 4w ago | 8-K | $84.95 $84.95 | · 0.00% | ▼ −0.44% | — |
Aug 14, 2026 7w ago | 8-K | $84.70 $84.75 | ▲ +0.06% | ▲ +0.53% | — |
Aug 3, 2026 8w ago | Press Release | $83.86 $84.00 | ▲ +0.17% | ▲ +0.37% | — |
Jul 10, 2026 12w ago | DEFA14A | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jul 10, 2026 12w ago | 8-K | $83.67 $83.71 | ▲ +0.05% | ▼ −0.31% | — |
Jun 30, 2026 13w ago | Press Release | $38.68 $42.23 | ▲ +9.18% | ▲ +9.31% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Jun 14, 2026 15w ago | Press Release | $35.12 $35.00 | ▼ −0.34% | ▲ +0.25% | — |
Showing 10 of 15
US Market Status
Market Closed — Opens Mon (38h 31m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access